Brief: BiomX Announces Positive Results From Part 1 Of The Phase 1B/2A Study Evaluating BX004 For Treatment Of Chronic Pulmonary Infections In Patients With Cystic Fibrosis

Biomx

22/02/2023 11:34

Feb 22 (Reuters) - Biomx Inc  PHGE.A :
    * BIOMX ANNOUNCES POSITIVE RESULTS FROM PART 1 OF THE PHASE
1B/2A
STUDY EVALUATING BX004 FOR TREATMENT OF CHRONIC PULMONARY
INFECTIONS IN PATIENTS WITH CYSTIC FIBROSIS
    * BIOMX INC: BX004 THERAPY SAFE AND WELL-TOLERATED ACROSS
ALL
PATIENTS AND DOSE LEVELS
    * BIOMX INC: PRELIMINARY SIGNALS OF EFFICACY ALSO OBSERVED,
WITH
NOTABLE REDUCTIONS IN BACTERIAL BURDEN
    * BIOMX INC: DOSING IN PATIENTS IN PART 2 INITIATED, RESULTS
EXPECTED IN Q3 23

Source text for Eikon:  ID:nGNX6BD2pN 
Further company coverage:  PHGE.A 
 ((Reuters.Briefs@thomsonreuters.com;))